Gram-Positive Coverage of Meropenem and Polymyxin
Meropenem provides moderate gram-positive coverage against methicillin-susceptible staphylococci and most streptococci, but polymyxin has NO gram-positive activity whatsoever.
Meropenem Gram-Positive Spectrum
Meropenem demonstrates activity against specific gram-positive organisms, though this is not its primary strength 1:
Organisms Covered:
- Enterococcus faecalis (vancomycin-susceptible isolates only)
- Staphylococcus aureus (methicillin-susceptible isolates ONLY - MSSA)
- Streptococcus agalactiae (Group B Strep)
- Streptococcus pneumoniae (penicillin-susceptible isolates only)
- Streptococcus pyogenes (Group A Strep)
- Viridans group streptococci
Critical Limitations:
Meropenem has NO activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE) 1. This is explicitly stated in the FDA label and represents a major gap in coverage.
The drug is 4- to 8-fold less active against oxacillin-susceptible staphylococci compared to imipenem 2, and only has moderate activity against Enterococcus faecalis (mean MIC 5 mg/L) 3.
Polymyxin Gram-Positive Coverage
Polymyxin (both polymyxin B and colistin/polymyxin E) has ZERO gram-positive activity 4. The FDA label explicitly states: "All gram positive bacteria, fungi, and gram-negative cocci are resistant to polymyxin B" 4.
Polymyxin's mechanism of action—disrupting bacterial cell membranes by targeting lipopolysaccharide in the outer membrane—only works against gram-negative bacteria 5. The gram-positive cell wall structure renders these organisms inherently resistant.
Clinical Implications
When using these antibiotics for empiric therapy:
- If gram-positive coverage is needed (particularly MRSA, enterococci, or resistant streptococci), you MUST add a separate agent such as vancomycin or linezolid 6
- Meropenem alone may suffice for polymicrobial infections where only methicillin-susceptible staphylococci or susceptible streptococci are concerns
- Polymyxin contributes nothing to gram-positive coverage and should never be relied upon for these organisms
The WHO guidelines recognize this limitation—when recommending meropenem for severe intra-abdominal infections, they note that ampicillin may need to be added for enterococcal coverage if the regimen doesn't otherwise cover these organisms 6.